At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...

Pre-earnings options volume in Vertex is normal with calls leading puts 7:4. Implied volatility suggests the market is anticipating a move near ...

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...

Adjusted earnings of $1.04 billion, or $3.98 per share, fell from $1.1 billion, or $4.20 per share, a year earlier, slightly short of estimates. Vertex pointed to an increase in operating ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations , with sales up 15.7% year on year to $2.91 billion. The company ...

For Q4, Vertex (NASDAQ:VRTX) reported non-GAAP EPS of $3.98 on net product revenue of $2.91B. Analysts, on average, had been expecting non-GAAP EPS of $4.02 on revenue of $2.78B. Looking ahead ...

Answering SPJA queries under differential privacy (DP), including graph-pattern counting under node-DP as an important ...

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported fourth-quarter profit of $913 million. The Boston-based company said it had net income of $3.50 per share.

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...